Belumosudil ( DrugBank: Belumosudil )

2 diseases

ID	Disease name (Link within this page)	Number of trials
51	Scleroderma	2
85	Idiopathic interstitial pneumonia	1

51. Scleroderma

Clinical trials : 525 / Drugs : 565 - (DrugBank : 148) / Drug target genes : 114 - Drug target pathways : 217

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04680975 (ClinicalTrials.gov)	March 3, 2021	11/12/2020	Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis	A Phase 2, Open-label Multicenter Study to Evaluate the Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis (dcSSc)	Diffuse Cutaneous Systemic Sclerosis	Drug: Belumosudil	Kadmon, a Sanofi Company	NULL	Completed	18 Years	N/A	All	10	Phase 2	United States
2	NCT03919799 (ClinicalTrials.gov)	June 26, 2019	21/11/2018	KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis	A Phase 2, Randomized, Placebo-controlled, Double-blind, Open-label Extension Multicenter Study to Evaluate the Efficacy and Safety of Belumosudil (KD025) in Subjects With Diffuse Cutaneous Systemic Sclerosis	System; Sclerosis;Diffuse Cutaneous Systemic Sclerosis	Drug: Belumosudil (KD025);Drug: Placebo	Kadmon, a Sanofi Company	NULL	Terminated	18 Years	100 Years	All	60	Phase 2	United States

Clinical trials : 627 / Drugs : 443 - (DrugBank : 120) / Drug target genes : 99 - Drug target pathways : 212

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02688647 (ClinicalTrials.gov)	May 26, 2016	18/2/2016	A 2-Part, Phase 2 Open-label and Crossover Study of Belumosudil for Treatment of Idiopathic Pulmonary Fibrosis	A Randomized, Phase 2, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Activity of Belumosudil in Subjects With Idiopathic Pulmonary Fibrosis (IPF)	Idiopathic Pulmonary Fibrosis	Drug: Belumosudil;Other: BSC	Kadmon Corporation, LLC	NULL	Completed	18 Years	N/A	All	76	Phase 2	United States